Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted share Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) Q3 2024 ...
Eton Pharmaceuticals, Inc. is rated Buy with revenue growth, FCF positivity & declining SG&A margins support. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results